You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. A244-052: Dynamic Synthetic Tissues for Medical Simulation and Training

    Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 07-29-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biotechnology, Advanced Materials OBJECTIVE: Develop a material-based solution which can demonstrate prolonged casualty care (PCC), nursing care, and trauma scenarios while dynamically changing the patient state based on the care being provided. DESCRIPTION: Human patient simulators leverage unreliable mechanical air bladders, anatomically inaccurate ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  2. A244-041: Electromagnetic Protection Coating for Artillery Projectiles

    Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 07-29-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Advanced Materials The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical data, or the Export Administration Regulation (EAR), 15 CFR Parts 730-774, which controls ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  3. A244-044: Electronic quality ferroelectric III-Nitride epitaxy for device heterostructures

    Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 07-29-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Hypersonics OBJECTIVE: To develop single crystalline epitaxial thin films and heterostructure of group III-IIIb-Nitride thin films for electronic device applications. The processes used should be scalable to 4-inch diameter wafer sizes or larger. DESCRIPTION: Since 2019 there have been demonstrations of ferroelectric III-Nitride semiconductors with p ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  4. RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning ( ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning (ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are u ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-23-069: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)

    Release Date: 01-03-2023Open Date: 03-05-2023 Due Dates: Multiple Close Date: 09-06-2025

    The goal of this FOA is to support the commercialization of SBIR/STTR-funded pain management technologies through the addition of an experienced entrepreneur within small business leadership teams and by supporting private fundraising and partnership activities. This Commercialization Readiness Pilot (CRP) funding opportunity is specifically open to Small Business Innovation Research (SBIR) and Sm ...

    SBIR/STTRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

    Release Date: 09-15-2022Open Date: 12-04-2022 Due Dates: Multiple Close Date: 04-05-2025

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-NS-23-007: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)

    Release Date: 09-15-2022Open Date: 12-04-2022 Due Dates: Multiple Close Date: 04-05-2025

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. A244-046: High Power and Torque Electric Motors for Direct-Drive Rotorcraft Applications

    Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 07-29-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Renewable Energy Generation and Storage OBJECTIVE: Identify and design an electric motor architecture enabling high power and torque output at motor rotational speeds and system weights suitable for direct-drive rotorcraft applications such as single main rotor helicopters. Build and demonstrate a prototype motor to substantiate weight and performance p ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  10. A244-032: High-Power Single Mode Diode Bars

    Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 07-29-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Integrated Sensing and Cyber; Directed Energy (DE); OBJECTIVE: Develop a diode bar with multi-watt (5-10W) power output per emitter that maintains single mode operation when coupled to an external wavelength beam combiner. DESCRIPTION: This topic seeks to enable power scaling in direct diode high energy lasers (HELs) while maintaining single mode ope ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
US Flag An Official Website of the United States Government